Skip to main content
profile image
Selected Works of Brian D. Piening, PhD
Article
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Journal for ImmunoTherapy of Cancer (2020)
  • Yoshinobu Koguchi, Providence Cancer Institute, Portland, OR, USA
  • Noriko Iwamoto, Shimadzu Scientific Instruments, Bothell, WA, USA
  • Takashi Shimada, Shimadzu Scientific Instruments, Bothell, WA, USA
  • Shu-Ching Chang, Providence St. Joseph Health, Portland, OR, USA
  • John Cha, Providence Cancer Institute, Portland, OR, USA
  • Brian D. Piening, Providence Cancer Institute, Portland, OR, USA
  • Brendan Curti, Providence Cancer Institute, Portland, OR, USA
  • Walter Urba, Providence Cancer Institute, Portland, OR, USA
  • William L Redmond, Providence Cancer Institute, Portland, OR, USA
Link
Disciplines
Publication Date
November 1, 2020
DOI
10.1136/JITC-2020-SITC2020.0760
Citation Information
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, et al.. "760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab" Journal for ImmunoTherapy of Cancer Vol. 8 (2020)
Available at: http://works.bepress.com/brian-piening/10/